

THE ROLE OF RADIOTHERAPY IN MANAGEMENT OF CANCER OF OROPHARYNX



ESSAY

*Submitted for Partial Fulfilment of
M.Sc. DEGREE
In*

RADIATION ONCOLOGY & NUCLEAR MEDICINE

By

HOSSAM AHMED MAHER MOHAMED

M.B.,B.Ch.

616.99432

H. A

Supervisors

Dr. SALWA MASSOUD IBRAHIM

Assistant Professor of Radiation Oncology and Nuclear Medicine,
Faculty of Medicine,
Ain Shams University

Dr. SOHEIR HELMY MAHMOUD

Assistant Professor of Radiation Oncology and Nuclear Medicine,
Faculty of Medicine
Ain Shams University


Dr. SOHEIR SAYED ISMAIL

Assistant Professor of Radiation Oncology and Nuclear Medicine,
Faculty of Medicine
Ain Shams University



**Faculty of Medicine
Ain Shams University**

1992





TO MY FAMILY

ACKNOWLEDGEMENT

I would like to express my profound gratitude and sincere appreciation to my Prof.Dr. LAILA FARIS, Head of Radiation Oncology & Nuclear Medicine Dept., Faculty of Medicine, Ain Shams University, from whom I learned a lot both practically and scientifically and for her great and continuous support and warm advice.

I was fortunate to carry out this work under the guidance of Asst. Prof.Dr. SALWA MASSOUD Assistant Professor of Radiation Oncology & Nuclear Medicine Dept., Faculty of Medicine, Ain Shams University. It was through her enthusiastic cooperation, infailing help, advice, support and encouragement, meticulous revision of every possible detail that this work would come to existence.

I am greatly indebted to Asst. Prof.Dr. SOHEIR HELMY Assistant Professor of Radiation Oncology & Nuclear Medicine Dept., Faculty of Medicine, Ain Shams University for all the help, guidance and encouragement during the preparation of this essay.

To Asst. Prof.Dr. SOHEIR ISMAIL Assistant Professor of Radiation Oncology & Nuclear Medicine Dept., Faculty of Medicine, Ain Shams University. I owe what is beyond

expression for her valuable guidance and encouragement.

Lastly but by no means the least, I thank all my professors and colleagues for their sincere help and cooperation during the accomplishment of this work.

TABLE OF CONTENTS

- INTRODUCTION AND AIM OF WORK	1
- REVIEW OF LITERATURE	4
- ANATOMY	4
- INCIDENCE	13
- ETIOLOGY	29
- CLINICAL FEATURES	35
- DIAGNOSIS	39
- PATHOLOGY	55
- METHODS OF SPREAD	76
- STAGING	82
- TREATMENT	86
- SURGERY	86
- RADIATION THERAPY	95
- BRACHYTHERAPY	129
- CHEMOTHERAPY	158
- NEW TRENDS IN TREATMENT OF OROPHARYNGEAL CANCER	177
- PROGNOSIS	179
- SUMMARY	186
- REFERENCES	188
- ARABIC SUMMARY	

LIST OF ABBREVIATIONS

AF	Accelerated Fractionation
AJCC	American Joint Committee Against Cancer.
ASRO & NMD	AinShams Radiation Oncology and Nuclear Medicine Department
BSO	Buthionine Sulfoxamine
C	Initial Activity of the Isotope
CDDP	Cisplatinum
cGy	certy Gray
CHART	Continuous Hyperfractionation Accelerated Radiation Therapy
CO₂	Carbon Dioxide
Co⁶⁰	Cobalt ⁶⁰ Teletherapy
CR	Complete Response
CRMCA	Cancer Registry of the Metropolitan Cairo Area.
CT	Computerized Tomography
DFS	Disease Free Survival
DH	Diffuse Histiocytic
DLPD	Diffuse Lymphocytic Poorly Differentiated
DLWD	Diffuse Lymphocytic Well Differentiated
DM	Diffuse Mixed Lymphocytic and histiocytic
DNA	Deoxyribo-Nucleic Acid.
D 5/0.45 NS	5% Dextrose in 0.45% Normal Saline
DU	Diffuse Undifferentiated.
DXM	Dexamethasone.
Ed	Editor(s)
EGFRs	Epidermal Growth Factor Receptors
EORTC	Uropean Organization for Research on Treatment of Cancer.
f	Correction Factor.
5 FU	5 Fluorouracil.

<i>T</i>	Gamma Ray Constant
<i>Gd-DTPA</i>	Godaluminium-Diethylene Triamin Penta-Acetic Acid.
<i>GG</i>	Guided Gutter
<i>GSH</i>	Glutathione
<i>h</i>	Distance
<i>H_E</i>	Equivalent Hourse.
<i>HF</i>	Hyper Fractionation
<i>HLac</i>	Sublines of Human Squamous Carcinoma Cells Re- sistent to Cisplatin.
<i>HN SCCA</i>	Head and Neck Squamous Cell Carcinoma Antigen.
<i>HVL</i>	Half Value Layer.
<i>I¹²⁵</i>	Iodine-125
<i>IL-2</i>	Interleukin 2
<i>In-III CEA</i>	Indium-III Lbelled Carcino-Embryonic Antigen.
<i>Ir¹⁹²</i>	Iridum- ¹⁹² .
<i>LASA</i>	Lipid-Associated Sialic Acid.
<i>LSA</i>	Lipid-Bourd Sialic Acid.
<i>M</i>	Number of Milligram hours per 1000 roentgen
<i>mc</i>	Millicurie
<i>MCP</i>	Metaclopromide.
<i>mEq Kcl</i>	milli Equivelant Potassium Chloride.
<i>MeV</i>	Million Electron Valts.
<i>M/F</i>	Male to Female Ratio
<i>MPC</i>	Multiple Primary Cancers.
<i>MRI</i>	Magnetic Resonance Imaging
<i>MV</i>	Megavalts.
<i>NCI</i>	National Cancer Institute
<i>NH</i>	Nodular Histocytic.
<i>NHL</i>	Non Hodgkin's Lymphoma.
<i>NLPD</i>	Nodular Lymphocytic Poorly Differentiated
<i>NLWD</i>	Nodular Lymphocytic Well Differentiated.
<i>NM</i>	Nodular Mixed Lymphocytic and Histocytic.
<i>OC</i>	Oropharyngeal Carcinoma.
<i>ORs</i>	Odd Ratios.

PBH	Protein-Baurd Hexoses
PC	Precancerous Lesions
Pt	Platinum
PT	Plastic Tube.
R	Roentgen.
Ra²²⁶	Radium ²²⁶ .
RND	Radical Neck Dissection
RR	Relative Risk
SEER	Survillance Epidemiology and End Results.
SIADH	Syndrome of Inappropriate Antidiuretic Horone.
SPECT	Single Photon Emission Computerized Tomography.
SSD	Source Surface Distance.
T	Half Life.
TABE	Tumour-Associated Blood Eosinophilia.
TATE	Tumour-Associated Tissue Eosinophilia.
Tc^{99m} DMSA	Technetium ^{99m} Dimercaptosuccinic Acid.
TNM	Tumour Node Metastasis.
TSA	Total Sialic Acid.
UICC	International Union Against Cancer.
UIHC	University of Iowa Hospital and Clinics.
V	Volume.
VRP	Verapamil
WHO	World Health Organization.
WR	Waldeyer's Ring.

INTRODUCTION AND AIM OF WORK

INTRODUCTION AND AIM OF WORK

The oropharynx includes four areas: the base of the tongue, the tonsillar region (tonsillar fossae and tonsillar pillars), the soft palate, and the portion of the pharyngeal wall between the pharyngoepiglottic fold and the nasopharynx (Million et al., 1989).

Oropharyngeal carcinoma constitutes about 9 % of head and neck cancers and about 0.3% of all cancer cases (Ibrahim, 1992 and Sherif and Ibrahim, 1987).

The etiology of oropharyngeal tumors is not precisely known, however several factors including genetic susceptibility, viruses and ionising radiation are incriminated (Gluckman and Thompson, 1989).

Early detection of oropharyngeal tumors with serum glucoconjugates tumor markers and radionuclide imaging are now used with high sensitivity and specificity (Watkinson et al., 1987 and Bina et al., 1991).

For many years radiotherapy for oropharyngeal cancers was regarded as the treatment of choice. The poor prognosis seems related to the inaccessability of the area of examination and early cervical lymph node metastasis. Now

surgery or radiotherapy is used effectively for small limited cancers (T1 and T2 lesions), while combined therapy (surgery and radiotherapy with or without chemotherapy) is planned for more advanced lesions (T3 and T4) and for tumors of some areas. for example, the base of the tongue (Gluckman and Thompson, 1989).

Many radiotherapists continue to offer radiation therapy as the primary mode of therapy for tumors of the tonsil as well as the regional lymphatics (Perez, 1992).

Multimodality approach of preoperative chemotherapy (methotrexate with leucovorin rescue, cisplatinum and bleomycin) followed by radiation therapy and surgery appears to offer a better survival and a promising approach in stage III and IV oropharyngeal tumors (Zidan and Kuten, 1987).

In recent studies chemotherapy using cisplatinum, continuous infusion of 5-fluorouracil and high dose leucovorin is proved to be effective in patients of recurrent or newly diagnosed metastatic squamous cell carcinoma (Al Saraf, 1988).

Hyperfractionation for T2, T3 and T4 cancers of the

oropharynx gives a better local control and prolonged survival than the continuous course with once-a-day irradiation (Parsons et al., 1988).

Brachytherapy with removable or permanent implants, is site specific and an effective treatment modality for advanced and recurrent oropharyngeal tumors (Wang, 1990).

AIM OF THE WORK:

The current essay will review the epidemiology, clinicopathological classification, management, prognosis and end results of treatment of oropharyngeal carcinoma.

Different fractionation schedules of radiation therapy and recent advances in brachytherapy will be discussed.

REVIEW OF LITERATURE